T(8;21)(q22;q22) fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression

Blood

Volumn 112, Issue 4, 2008, Pages 1392-1401

  Okumura, Akiko J ^a,b   Peterson, Luke F ^a   Okumura, Fumihiko ^a   Boyapati, Anita ^a   Zhang, Dong Er ^a,b,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; HYBRID PROTEIN AML1 ETO; SEPARASE; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; DNA BINDING PROTEIN; OLIGONUCLEOTIDE; ONCOPROTEIN; RUNX1 PROTEIN, HUMAN;

ARTICLE; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DNA BINDING; DNA LIBRARY; DNA SCREENING; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; REGULATORY SEQUENCE; WESTERN BLOTTING; BINDING SITE; CHROMOSOME 21; CHROMOSOME 8; ENHANCER REGION; GENE LIBRARY; GENE TRANSLOCATION; GENETICS; METABOLISM; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION; GENE LIBRARY; HUMANS; OLIGONUCLEOTIDES; ONCOGENE PROTEINS, FUSION; PROTEIN BINDING; REPETITIVE SEQUENCES, NUCLEIC ACID; TRANSLOCATION, GENETIC;

EID: 51649109222     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-124735     Document Type: Article

References (69)

1. Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol. 1999; 106:296-308.
2. Friedman AD. Leukemogenesis by CBF oncoproteins. Leukemia. 1999;13:1932-1942.
3. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene. 2000;245:223-235.
4. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 1995;86:1-14.
5. Miyoshi H, Shimizu K, Kozu T, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA. 1991;88:10431-10434.
6. Miyoshi H, Kozu T Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 1993;12:2715-2721.
7. Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol. 1993;13:6336-6345.
8. Ogawa E, Inuzuka M, Maruyama M, et al. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology. 1993;194:314-331.
9. Speck NA, Stacy T Wang Q, et al. Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res. 1999;59:1789s-1793s.
10. Wang SW, Speck NA. Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol. 1992;12:89-102.
11. Westendorf JJ, Hiebert SW. Mammalian runt- domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. J Cell Biochem. 1999;(suppl 32-33):51-58.
12. Petrovick MS, Hiebert SW, Friedman AD, et al. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol. 1998;18:3915-3925.
13. Kanno T, Kan no Y, Chen LF, et al. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol Cell Biol. 1998;18: 2444-2454.
14. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML 1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
15. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA. 1996;93:3444-3449.
16. Frank R, Zhang J, Uchida H, et al. The AML1/ ETO fusion protein blocks trans activation of the GM-CSF promoter by AML1B. Oncogene. 1995; 11:2667-2674.
17. Hohaus S, Petrovick MS, Voso MT, et al. PU. 1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol. 1995; 15:5830-5845.
18. Nuchprayoon I, Meyers S, Scott LM, et al. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta protooncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol. 1994;14:5558-5568.
19. Uchida H, Zhang J, Nimer SD. AML1 Aand AML1B can transactivate the human IL-3 promoter. J Immunol. 1997;158:2251-2258.
20. Zhang DE, Fujioka K, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol. 1994;14:8085-8095.
21. Zhang DE, Hetherington CJ, Meyers S, et al. CGAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16:1231-1240.
22. Sun W, Downing JR. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood. 20Q4;104:3565- 3572.
23. Taniuchi I, Osato M, Egawa T. et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell. 2002:111:621-633.
24. Tsuzuki S, Hong D, Gupta R, et al. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med. 2007; 4:e172, 880-896.
25. Peterson LF, Boyapati A, Ahn EY, et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8; 21) transcripts. Blood. 2007;110:799-805.
26. Calabi F, Pannell R, Pavloska G. Gene targeting reveals a crucial role for MTG8 in the gut. Mol Cell Biol. 2001 ;21:5658-5666.
27. Gelmetti V, Zhang J, Fanelli M, et al. Aberrant recruitment of the nuclear receptor corepressor- histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998:18:7185-7191.
28. Lutterbach B. Westendorf JJ, Linggi B, et al. ETO. atarget of t(8;21) in acute leukemia, interacts with the N-CoR and mSinS corepressors. Mol Cell Biol. 1998;18:7176-7184.
29. Wang J, Hoshino T, Redner RL. Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA. 1998;95:10860-10865.
30. Kamachi Y, Ogawa E, Asano M, et al. Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J Virol. 1990;64:4808-4819.
31. Thornell A, Hallberg B, Grundstrom T. Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences. J Virol. 1991;65:42-50.
32. Melnikova IN, Crute BE, Wang S, Speck NA. Sequence specificity of the core-binding factor. J Virol. 1993;67:2408-2411.
33. Yan M, Burel SA, Peterson LF, et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interact- ing region strongly induces leukemia development. Proc Natl Acad Sci USA. 2004;101: 17186-17191.
34. Yan M, Kanbe E, Peterson LF et al. A previously unidentified alternatively spliced isotorm of t(8:21) transcript promotes leukemogenesis. Nat Med. 2006;12:945-949.
35. Burel SA, Harakawa N, Zhou L, et al. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol. 2001;21: 5577-5590.
36. Zhang DE, Hetherington CJ, Chen HM, Tenen DG. The macrophage transcription factor PU. 1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. Mol Cell Biol. 1994;14:373-381.
37. Peterson LF, Boyapati A. Ranganathan V. et al. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol. 2005;25:10205-10219.
38. Joo A, Aburatani H, Morii E, Iba H, Yoshimura A. STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression. Oncogene. 2004;23:726-734.
39. Severa M, Coccia EM, Fitzgerald KA. Toll-like receptor-dependent and -independent viperin gene expression and counter-regulation by PRDI- binding factor-1/BLIMP1. J Biol Chem. 2006;281: 26188-26195.
40. Takahashi Y. Rayman JB. Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev. 2000;14:804-816.
41. Okumura F Zou W, Zhang DE. ISG15 modification of the elF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev. 2007:21:255-260.
42. Peterson LF Boyapati A, Ranganathan V, et al. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol. 2005;25:10205- 10219.
43. Okumura AJ, Peterson LF. Lo MC, Zhang DE. Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells. Exp Hematol. 2007:35:978-988.
44. Boyapati A. Yan M. Peterson LF. et al. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood. 2007;109:3963- 3971.
45. Asou H. Tashiro S. Hamamoto K, et al. Establishmerit of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991;77:2031-2036.
46. Peterson LF. Wang Y, Lo MC. et al. The multifunctional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia. 2007;21:2010-2019.
47. Brekken RA. Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001 ;19:816-827.
48. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem. 2004:92:679-690.
49. Lehmann S, O'Kelly J, Raynaud S, et al. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21: 1931-1936.
50. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU. 1. Nat Genet. 2004;36:624-630.
51. Liu Y, Chen W, Gaudet J, et al. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell. 2007;11:483-497.
52. Zou H, Stemman O, Anderson JS, Mann M, Kirschner MW. Anaphase specific auto-cleavage of separase. FEBS Lett. 2002;528:246-250.
53. Chestukhin A, Pfeffer C, Milligan S, DeCaprio JA, Pellman D. Processing, localization, and requirement of human separase for normal anaphase progression. Proc Natl Acad Sci USA. 2003;100: 4574-4579.
54. Li Y, Okuno Y. Zhang P, et al. Regulation of the PU. 1 gene by distal elements. Blood. 2001;98: 2958-2965.
55. Hines R, Boyapati A, Zhang DE. Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Blood Cells Mol Dis. 2007;39:297-306.
56. Salat D, Liefke R, Wiedenmann J, Borggrefe T, Oswald F. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-J{kappa}/ SHARP-mediated repression of Notch target genes. Mol Cell Biol. 2008;28:3502-3512.
57. Liu Y, Cheney MD, Gaudet JJ, et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO!s activity. Cancer Cell. 2006;9:249-260.
58. Minucci S, Maccarana M, Cioce M, et al. Oli- gornerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000;5:811-820.
59. Hug BA, Lee SY, Kinsler EL, Zhang J, Lazar MA. Cooperative function of Arnl1 -ETO corepressor recruitment domains in the expansion of primary bone marrow cells. Cancer Res. 2002;62:2906- 2912.
60. Kitayner M, Rozenberg H, Kessler N, et al. Structural basis of DNA recognition by p53 tetramers. Mol Cell. 2006;22:741-753.
61. Soldaini E, John S, Moro S, et al. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol. 2000; 20:389-401.
62. Jacobson EM, Li P, Leon-del-Rio A, Rosenfeld MG, Aggarwal AK. Structure of Pit-1 POU domain bound to DNA as a dimer: unexpected arrangement and flexibility. Genes Dev. 1997;11:198-212.
63. Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AM L1 (Runx1)-CBF beta complex functions as a DNA-induced molecular clamp. Nat Struct Biol. 2001 ;8:371-378.
64. Bartfeld D, Shimon L, Couture GC, et al. DNA recognition by the RUNX1 transcription factor is mediated by an allosteric transition in the RUNT domain and by DNA bending. Structure. 2002;10: 1395-1407.
65. Li Z, Yan J, Matheny CJ, et al. Energetic contribution of residues in the Runxl Runt domain to DNA binding. J Biol Chem. 2003;278:33088- 33096.
66. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell. 2003;4:99-110.
67. Kumada K, Yao R. Kawaguchi T, et al. The selective continued linkage of centromeres from mitosis to interphase in the absence of mammalian separase. J Cell Biol. 2006;172:835-846.
68. Wirth KG, Wutz G, Kudo NR, et al. Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression. J Cell Biol. 2006;172:847-860.
69. Shepard JL, Amatruda JF, Finkelstein D, et al. A mutation in separase causes genome instability and increased susceptibility to epithelial cancer. Genes Dev. 2007;21:55-59.